These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 21447798)

  • 21. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
    Van Schaeybroeck S; Kyula JN; Fenton A; Fenning CS; Sasazuki T; Shirasawa S; Longley DB; Johnston PG
    Cancer Res; 2011 Feb; 71(3):1071-80. PubMed ID: 21148749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
    Gong J; Chen Y; Yang L; Pillai R; Shirasawa S; Fakih M
    Anticancer Res; 2017 Jun; 37(6):2831-2838. PubMed ID: 28551618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim.
    Meng J; Fang B; Liao Y; Chresta CM; Smith PD; Roth JA
    PLoS One; 2010 Sep; 5(9):e13026. PubMed ID: 20885957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
    Sale MJ; Cook SJ
    Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
    Ji H; Wang Z; Perera SA; Li D; Liang MC; Zaghlul S; McNamara K; Chen L; Albert M; Sun Y; Al-Hashem R; Chirieac LR; Padera R; Bronson RT; Thomas RK; Garraway LA; Jänne PA; Johnson BE; Chin L; Wong KK
    Cancer Res; 2007 May; 67(10):4933-9. PubMed ID: 17510423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.
    Bass A
    J Clin Oncol; 2011 Jul; 29(19):2728-9. PubMed ID: 21646605
    [No Abstract]   [Full Text] [Related]  

  • 32. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
    Temraz S; Mukherji D; Shamseddine A
    Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
    Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K
    Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.
    Bid HK; Kibler A; Phelps DA; Manap S; Xiao L; Lin J; Capper D; Oswald D; Geier B; DeWire M; Smith PD; Kurmasheva RT; Mo X; Fernandez S; Houghton PJ
    Clin Cancer Res; 2013 Dec; 19(24):6716-29. PubMed ID: 24132923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
    Andrews MC; Behren A; Chionh F; Mariadason J; Vella LJ; Do H; Dobrovic A; Tebbutt N; Cebon J
    J Clin Oncol; 2013 Dec; 31(35):e448-51. PubMed ID: 24190114
    [No Abstract]   [Full Text] [Related]  

  • 38. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
    Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
    Kim EY; Kim A; Kim SK; Chang YS
    Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
    Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
    Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.